An interim final rule placing the newly approved drug Syndros in Schedule II has been finalized without change (82 Fed. Reg. 55504, Nov. 21, 2017). Syndros consists of dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in oral solution. The drug was approved by the U.S. Food and Drug Administration on July 1, 2016, for the treatment of anorexia associated with weig... Read More